These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 38310976)

  • 1. Exploring 2-methyl-substituted vitamin K
    Koharazawa R; Hayakawa M; Takeda K; Miyazaki K; Tode C; Hirota Y; Suhara Y
    Bioorg Med Chem Lett; 2024 Mar; 100():129642. PubMed ID: 38310976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of Vitamin K3 and its analogues as covalent inhibitors of SARS-CoV-2 3CL
    Wang R; Hu Q; Wang H; Zhu G; Wang M; Zhang Q; Zhao Y; Li C; Zhang Y; Ge G; Chen H; Chen L
    Int J Biol Macromol; 2021 Jul; 183():182-192. PubMed ID: 33901557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chetomin, a SARS-CoV-2 3C-like Protease (3CL
    Ibrahim MAA; Abdelrahman AHM; Mohamed DEM; Abdeljawaad KAA; Naeem MA; Gabr GA; Shawky AM; Soliman MES; Sidhom PA; Paré PW; Hegazy MF
    Viruses; 2023 Jan; 15(1):. PubMed ID: 36680290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of apigenin-based biflavonoid derivatives as potential therapeutic agents against viral protease (3CLpro) of SARS-CoV-2 via molecular docking, molecular dynamics and quantum mechanics studies.
    Abdizadeh R; Hadizadeh F; Abdizadeh T
    J Biomol Struct Dyn; 2023; 41(13):5915-5945. PubMed ID: 35848354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multidimensional virtual screening approaches combined with drug repurposing to identify potential covalent inhibitors of SARS-CoV-2 3CL protease.
    Wang Y; Gao Q; Yao P; Yao Q; Zhang J
    J Biomol Struct Dyn; 2023; 41(24):15262-15285. PubMed ID: 36961210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ensitrelvir is effective against SARS-CoV-2 3CL protease mutants circulating globally.
    Kawashima S; Matsui Y; Adachi T; Morikawa Y; Inoue K; Takebayashi S; Nobori H; Rokushima M; Tachibana Y; Kato T
    Biochem Biophys Res Commun; 2023 Feb; 645():132-136. PubMed ID: 36689809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chloropyridinyl Esters of Nonsteroidal Anti-Inflammatory Agents and Related Derivatives as Potent SARS-CoV-2 3CL Protease Inhibitors.
    Ghosh AK; Shahabi D; Yadav M; Kovela S; Anson BJ; Lendy EK; Bonham C; Sirohi D; Brito-Sierra CA; Hattori SI; Kuhn R; Mitsuya H; Mesecar AD
    Molecules; 2021 Sep; 26(19):. PubMed ID: 34641337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allosteric inhibitors of the main protease of SARS-CoV-2.
    Samrat SK; Xu J; Xie X; Gianti E; Chen H; Zou J; Pattis JG; Elokely K; Lee H; Li Z; Klein ML; Shi PY; Zhou J; Li H
    Antiviral Res; 2022 Sep; 205():105381. PubMed ID: 35835291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacoinformatics and molecular dynamics simulation studies reveal potential covalent and FDA-approved inhibitors of SARS-CoV-2 main protease 3CL
    Alamri MA; Tahir Ul Qamar M; Mirza MU; Bhadane R; Alqahtani SM; Muneer I; Froeyen M; Salo-Ahen OMH
    J Biomol Struct Dyn; 2021 Aug; 39(13):4936-4948. PubMed ID: 32579061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a simple, interpretable and easily transferable QSAR model for quick screening antiviral databases in search of novel 3C-like protease (3CLpro) enzyme inhibitors against SARS-CoV diseases.
    Kumar V; Roy K
    SAR QSAR Environ Res; 2020 Jul; 31(7):511-526. PubMed ID: 32543892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery and mechanism of action of Thonzonium bromide from an FDA-approved drug library with potent and broad-spectrum inhibitory activity against main proteases of human coronaviruses.
    Wang R; Zhai G; Zhu G; Wang M; Gong X; Zhang W; Ge G; Chen H; Chen L
    Bioorg Chem; 2023 Jan; 130():106264. PubMed ID: 36395603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiviral evaluation of hydroxyethylamine analogs: Inhibitors of SARS-CoV-2 main protease (3CLpro), a virtual screening and simulation approach.
    Gupta Y; Kumar S; Zak SE; Jones KA; Upadhyay C; Sharma N; Azizi SA; Kathayat RS; Poonam ; Herbert AS; Durvasula R; Dickinson BC; Dye JM; Rathi B; Kempaiah P
    Bioorg Med Chem; 2021 Oct; 47():116393. PubMed ID: 34509862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of Novel Drug Candidates for the Inhibition of Catalytic Cleavage Activity of Coronavirus 3CL-like Protease Enzyme.
    Gurung AB; Al-Anazi KM; Ali MA; Lee J; Farah MA
    Curr Pharm Biotechnol; 2022; 23(7):959-969. PubMed ID: 34097590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and synthesis of isatin derivatives as effective SARS-CoV-2 3CL protease inhibitors.
    Bao HL; Tu G; Yue Q; Liu P; Zheng HL; Yao XJ
    Chem Biol Drug Des; 2023 Oct; 102(4):857-869. PubMed ID: 37563791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Global prevalence of SARS-CoV-2 3CL protease mutations associated with nirmatrelvir or ensitrelvir resistance.
    Ip JD; Wing-Ho Chu A; Chan WM; Cheuk-Ying Leung R; Umer Abdullah SM; Sun Y; Kai-Wang To K
    EBioMedicine; 2023 May; 91():104559. PubMed ID: 37060743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The inhibitory effects of PGG and EGCG against the SARS-CoV-2 3C-like protease.
    Chiou WC; Chen JC; Chen YT; Yang JM; Hwang LH; Lyu YS; Yang HY; Huang C
    Biochem Biophys Res Commun; 2022 Feb; 591():130-136. PubMed ID: 33454058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methyl rosmarinate is an allosteric inhibitor of SARS-CoV-2 3 CL protease as a potential candidate against SARS-cov-2 infection.
    Li H; Sun M; Lei F; Liu J; Chen X; Li Y; Wang Y; Lu J; Yu D; Gao Y; Xu J; Chen H; Li M; Yi Z; He X; Chen L
    Antiviral Res; 2024 Apr; 224():105841. PubMed ID: 38408645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of Darunavir Derivatives for Inhibition of SARS-CoV-2 3CL
    Ma L; Xie Y; Zhu M; Yi D; Zhao J; Guo S; Zhang Y; Wang J; Li Q; Wang Y; Cen S
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In silico analysis and identification of antiviral coumarin derivatives against 3-chymotrypsin-like main protease of the novel coronavirus SARS-CoV-2.
    Abdizadeh R; Hadizadeh F; Abdizadeh T
    Mol Divers; 2022 Apr; 26(2):1053-1076. PubMed ID: 34213728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Danshensu inhibits SARS-CoV-2 by targeting its main protease as a specific covalent inhibitor and discovery of bifunctional compounds eliciting antiviral and anti-inflammatory activity.
    Wang R; Chen X; Li H; Chen X; Sun D; Yu D; Lu J; Xie Y; Zhang Q; Xu J; Zhang W; Chen H; Liu S; Chen L
    Int J Biol Macromol; 2024 Feb; 257(Pt 2):128623. PubMed ID: 38070810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.